Monkeypox Biology, Outcome, Transmission and Epidemiology (MBOTE) Study: Epidemiological and Pathophysiological Insights Through a Cross-sectional Survey (EPIC)

Status: Recruiting
Location: See all (2) locations...
Study Type: Observational
SUMMARY

This study aims to better understand how mpox is spreading in the DRC, how it affects different groups of people, and how well vaccines protect against it. The study is designed as a cross-sectional survey, meaning researchers will collect and analyze data from patients diagnosed with mpox at a single point in time. It will also use a case-control approach, comparing people who test positive for the virus to those who test negative, to identify risk factors and evaluate the effectiveness of the vaccine.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Apply to be tested for VMPX at HGR or another test center.

• Patients of all ages and sexes. However, minors under the age of 12 are excluded from questions on sex life.

• The patient or his/her culturally acceptable representative is willing and able to give informed consent for participation in the study.

Locations
Other Locations
Democratic Republic of the Congo
Masina Mpox Treatment Center
RECRUITING
Kinshasa
Masina Mpox Treatment Center
NOT_YET_RECRUITING
Kinshasa
Contact Information
Primary
Laurens Liesenborghs, MD, PhD
lliesenborghs@itg.be
00000000000
Backup
Sarah Houben, PhD
shouben@itg.be
Time Frame
Start Date: 2025-03-28
Estimated Completion Date: 2027-02-28
Participants
Target number of participants: 1000
Related Therapeutic Areas
Sponsors
Collaborators: University of Manitoba, Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo, Alliance for International Medical Action, Catholic University of Bukavu, Democratic Republic of Congo, European and Developing Countries Clinical Trials Partnership (EDCTP), University of Bern, University of California, Los Angeles, Institut de Recherche pour le Developpement
Leads: Institute of Tropical Medicine, Belgium

This content was sourced from clinicaltrials.gov